HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NCCAM Funding Hike Proposed By Bush Administration

This article was originally published in The Tan Sheet

Executive Summary

A 6.6% funding boost for the National Center for Complementary & Alternative Medicine falls toward the lower end of requested increases for NIH divisions under the Bush Administration's FY 2003 budget proposal

You may also be interested in...

Dietary Supplement Firms Eyed For More Frequent Inspections By FDA

FDA intends to reduce the time between inspections of dietary supplement firms

FDA Budget Includes 61% PDUFA Increase; Agency Wants Proposal By May

FDA aims to reach an agreement with industry on the framework for reauthorization of the Prescription Drug User Fee Act by May, Acting Senior Associate Commissioner for Management & Systems Jeff Weber said Feb. 5 during a press briefing on the FDA budget

CAM Bioterrorism, HIV/AIDS Research To Be Funded By NCCAM

Basic and clinical research on the potential benefits of CAM therapies for HIV/AIDS will be sponsored in 2003 by the National Center for Complementary & Alternative Medicine





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts